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Objectives: To examine synovial tissue (ST) predictors of clinical differentiation in patients
with seronegative undifferentiated peripheral inflammatory arthritis (UPIA).
Methods: Fourty-two patients with IgA/IgM-Rheumatoid Factor and anti-citrullinated
peptide antibodies negative UPIA, naive to Disease-Modifying Anti-Rheumatic Drugs,
underwent Gray Scale (GSUS) and power Doppler (PDUS) evaluation and Ultrasound
(US) guided ST biopsy. CD68, CD3, CD21, CD20, and CD31 synovial expression was
evaluated by immunohistochemistry. Whole ST microRNA expression was assessed
using miScript miRNA PCR Array. Peripheral blood (PB) and synovial fluid (SF) IL-6,
VEGF-A, and VEGF-D levels were measured by ELISA and ST TNF expression was
assessed by RT-PCR. Each patient was prospectively monitored and classified at
baseline and within 1 year as UPIA, Rheumatoid Arthritis (RA), Spondyloarthritis (SpA)
or Psoriatic Arthritis (PsA), respectively.
Results: At baseline, CD68+ cells were the most common cells within the lining
layer (p < 0.001) in seronegative UPIA, directly correlating with GSUS (R = 0.36;
p = 0.02) and PDUS (R = 0.55; p < 0.001). Synovial CD31+ vessels count directly
correlated with GSUS (R = 0.41; p = 0.01) and PDUS (R = 0.52; p < 0.001). During
the follow-up, 6 (14.3%) UPIA reached a definite diagnosis (2 RA, 2 SpA and 2 PsA,
respectively). At baseline, UPIA who differentiated had higher GSUS (p = 0.01), PDUS
scores (p = 0.02) and higher histological scores for CD68+ (p = 0.005 and p = 0.04
for lining and sublining respectively), sublining CD3+ cells (p = 0.002), CD31+ vessels
count (p < 0.001) and higher IL-6PB levels (p = 0.01) than patients who remained as
UPIA. MiRNA PCR Array showed that among the 86 tested miRNA species, at baseline,
miR-346 and miR-214 were significantly down-regulated (p = 0.02 for both) in ST of
UPIA who differentiated than in patients who remained as UPIA, inversely correlating with
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the lining CD68+ cells IHC score (R = −0.641; p = 0.048) and CD31+ vessels count
(R = −0.665; p = 0.036) and with higher baseline ST expression of TNF (p = 0.014).
Finally, logistic regression analysis demonstrated that baseline GSUS and PDUS scores
≥1.5 [OR:22.93 (95%CI:0.98–534.30)] and CD31+ vessels count ≥24.3 [OR:23.66
(95%CI:1.50–373.02)] were independent factors associated with the development of
definite arthritis.
Conclusions: MiRNA signature, histological and US features of ST may help in the
identification of seronegative UPIA with high likelihood of clinical differentiation toward
definite seronegative arthritis.
Keywords: undifferentiated peripheral inflammatory arthritis, synovial tissue biopsy, ultrasonography, microRNA,
predictor
INTRODUCTION
Undifferentiated Peripheral Inflammatory Arthritis (UPIA) is
a common diagnosis in daily practice at the first clinical
evaluation in rheumatological settings. However, the likelihood
of developing a well-defined rheumatic disease in UPIA patients
as well as the disease progression toward a defined diagnosis,
is still matter of debate. Multinational recommendations on
the management of UPIA patients have been produced (1),
since the future diagnosis and prognosis represent important
issues for clinical decision making, including the choice of
treatment. Testing for Rheumatoid Factor (RF) and/or anti-
citrullinated peptide antibodies (ACPA) should be performed in
the evaluation of UPIA patients, as these factors are predictive
of Rheumatoid Arthritis (RA) diagnosis and prognosis, although
negative tests do not exclude progression to RA (2–4).
Ultrasound (US) assessment may be an useful tool in the
management of UPIA patients, as the severity of US detected
synovitis in UPIA patients was shown to be a predictive factor
associated to RA progression (5). However, due to the scarcity of
evidences produced so far, its use is not recommended to increase
the diagnostic and prognostic power of the clinical examination
(6), as well as the use of synovial tissue (ST) biopsy as prognostic
tool to foresee the future development of definite diagnosis in
UPIA patients (7). In particular, very limited data are available
on the diagnostic and prognostic value of synovial tissue biopsy
in UPIA patients and regardless to ACPA and RF serological
status, synovial CD68 positivity can differentiate among RA,
Spondyloarthritis (SpA) and other diagnoses (8).
MicroRNA (miRNA) are small, noncoding, single-stranded
RNAs with crucial role in post-transcriptional gene regulation
(9), binding to the 3′-untraslated region (3′-UTR) of target
messenger RNA (mRNA) and inducing gene silencing by either
promoting mRNA degradation or transcript destabilization,
resulting in the suppression of target protein (9). Multiple
miRNAs have been demonstrated to act as critical epigenetic
components in the activation of the immune system in
inflammatory joints disease (9–11). To date, limited knowledge is
available about miRNAs expression in UPIA patients, with initial
data available only about the preclinical phase of seropositive
individuals (12, 13).
Based on that, the aims of the study were (i) to define the
histological features of ST in terms of CD68+, CD21+, CD3+,
CD20+ cells, and CD31+ vessels of IgA/IgM-RF and ACPA
negative, UPIA patients at first clinical examination; (ii) to dissect
the possible relation between histological parameters of ST with
Gray scale (GS) and Power Doppler (PDUS) scores; (iii) to
evaluate possible differences in the epigenetic (miRNA) signature
of seronegative UPIA patients based on the differentiation during
the follow-up and (iv) to test the prognostic power at baseline, of
histological, serological andUS parameters of ST inflammation in
foreseeing the future achievement of a definite arthritis diagnosis
in seronegative UPIA patients.
PATIENTS AND METHODS
Study Population
Consecutive patients with at least 1 active knee joint with
IgA/IgM-RF and ACPA negative UPIA, naive to any Disease
Modifying Anti-Rheumatic Drugs (DMARDs), were enrolled
in the study at the Division of Rheumatology–Fondazione
Policlinico Universitario A. Gemelli, Catholic University of
the Sacred Heart. At baseline, demographical, clinical and
inflammatory parameters were collected for each patient. Each
UPIA patient was tested for IgA and IgM-RF (Orgentec
Diagnostika, Bouty, UK) and ACPA (Menarini Diagnostics,
Italy) using commercial Enzyme-Linked Immunosorbent Assay
(ELISA) and ChemiLuminescence Immunoassay (CLIA) to
confirm the inclusion criteria fulfillment. At baseline, each
UPIA patient underwent genital and throat swabs to exclude
Reactive Arthritis (14), and X-Ray of hands and feet to
exclude marginal erosions. Each UPIA patient was then
treated with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
and chloroquine 250 mg/daily and followed every 3 months
for 1 year to assess the possible differentiation into known
defined arthritis (15–17). In particular, during the follow-up
seronegative UPIA patients were re-classified as Rheumatoid
Arthritis (RA) if >10 joints (at least 1 small joint) were
involved and abnormal C-Reactive Protein (CRP) or abnormal
Erythrocyte Sedimentation Rate (ESR) were present (15); as
having Psoriatic Arthritis (PsA) if at least 3 points were
fulfilled among the following: evidence of psoriasis, presence
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of psoriatic nail dystrophy, dactylitis, or radiographic evidence
of juxta-articular new bone formation on plain radiographs
of the hand or foot (16); or as having Spondyloarthritis
(SpA) if sacroiliitis was detected on imaging plus one or
more SpA features were fulfilled (inflammatory back pain,
arthritis, enthesitis, uveitis, dactylitis, psoriasis, inflammatory
bowel disease, good response to NSAIDs, family history of SpA,
Human Leukocyte Antigen (HLA)-B27 presence or elevated
CRP) (17). The study protocol was approved by the local
Ethical Committee (Fondazione Policlinico Universitario A.
Gemelli, Rome, Italy) and all subjects provided signed informed
consent.
US Assessment
At baseline, all UPIA patients underwent US assessment
following the same protocol (18). Briefly, each UPIA patient
underwent US evaluation using GS and PDUS technique
of the following joint sites bilaterally: transverse and
longitudinal scanning of dorsal and volar view of the II-III
metacarpophalangeal and proximal interphalangeal joints and
longitudinal and transverse scanning of the dorsal aspect of
the wrist (radiocarpal-intercarpal), bilateral knees and II-V
metatarsophalangeal joints. US assessment was performed by
one rheumatologist (LP) experienced in US, who was unaware
of the clinical and laboratory findings, using a commercially
available real-time scanner (MyLabTwice, Esaote) equipped
with a multi-frequency linear probe, working at 10–14 MHz.
Intra-reader reliability was 0.78. Semi-quantitative scoring
methods, which consists of a 0–3 scale, were used to grade
the presence of any synovial hypertrophy (SH) on GSUS
and its activity (PDUS) for each abovementioned joint, as
previously published (18). Briefly, SH was graded on the
basis of grayscale images using a semiquantitative scoring
method where 0 = no SH, 1 = minimal SH, 2 = moderate
SH, and 3 = severe SH, whereas PDUS was recorded using a
semiquantitative score where 0 = no PD signal, 1 = minimal
PD signal, 2 = moderate PD signal, and 3 = severe PD signal.
Two overall SH and PD scores were calculated as the sum of
scores obtained from each joint for SH and PD respectively
(18).
CD68, CD3, CD21, CD20, and CD31
Synovial Tissue Expression
At study entry, each UPIA patient underwent ultrasound guided
synovial tissue biopsy of the knee. Each tissue was tested
through immunohistochemistry for the presence of CD68, CD21,
CD3, CD20, and CD31 staining following the already published
protocol (19). Slides were examined by two independent
evaluators using a light microscope (Leica DM 2000) and all
tissues were evaluated using a numerical score based on the
number of CD68+, CD21+, CD3+, CD20+ cells in the lining
and sublining areas of the section (three different fields in each
section), with a score of 0 indicating no positive cells; 1 indicating
<10% positive cells; 2 indicating 10–50% positive cells; and 3
indicating >50% positive cells. CD31+ vessels count was done
as mean of the values from three different fields in each section
(19). The inter-rater agreement coefficient was assessed for each
single IHC marker (Supplementary Table 1).
MiRNA PCR Array on Synovial Tissue
Total RNA was isolated from synovial tissue of 10 UPIA
patients (6 patients who reached a definite diagnosis and
4 patients who remained as UPIA during the follow-up as
previously described) using the miRneasy kit (Qiagen). The
miScript Reverse Transcription kit (Qiagen) was used for cDNA
preparation and the miScript PreAMP PCR kit (Qiagen) was
used for cDNA pre-amplification following the manufacturer
instructions. miRNA profiling was performed using the Human
miScript miRNA PCR array (96 well format from Qiagen-
MIHS-111ZA). A set of controls were included on each plate
which enabled data analysis using 11Ct method of relative
quantification, assessment of reverse transcription performance,
and assessment of PCR performance. The miScript miRNA
PCR array enables SYBR Green-based real-time PCR analysis
using Biorad iQ5 real-time PCR system as follows: 95◦C
for 15min; 40 cycles of 94◦C for 15 s; 55◦C for 30 s; and
70◦C for 30 s. The relative expression was calculated using
the 11Ct method (relative gene expression = 2(1Cttest −
1Ctcontrol)] and is presented in fold increase relative to
control. The Web-based miScript miRNA PCR array data
analysis tool was used to analyze the real-time PCR data
(Qiagen).
TNF Expression in Whole Synovial Tissue
of UPIA Patients by RT-PCR
An iScriptTM cDNA Synthesis Kit (BioRad Laboratories,
Hercules, CA) was used for cDNA preparation (10 total
UPIA patients: 6 patients who differentiated toward definite
seronegative arthritis + 4 patients who remained as UPIA
during the follow-up). A FastStart Universal Probe Master
(04913949001) (Roche Diagnostics, Germany) was used for
RT-PCR using the following primers: human TNF (141083)
and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH,
101128) both from Roche Diagnostics, Germany. For the semi-
quantitative determination of the expression of human TNF and
control GAPDH in whole synovial tissue lysates,1Ct values were
generated after subtraction from the gene of interest (TNF) Ct
value of control (GAPDH).
IL-6, VEGF-A, and VEGF-D ELISA
Measurement
Each enrolled UPIA patient was tested for Interleukin-6 (IL-6),
Vascular Endothelial Growth Factor-A (VEGF-A) and VEGF-
D peripheral blood (PB) and synovial fluid (SF) (if available)
levels using commercial ELISA kits (all by R&D Systems,
United Kingdom). The sensitivity of the test was 0.70 pg/ml
for IL-6, 9.0 pg/ml for VEGF-A, and 11.4 pg/ml for VEGF-D
respectively.
Statistical Analysis
Statistical analysis was performed using SPSS version 21.0
(SPSS. Chicago. IL-USA) and Prism Software (Graph-Pad,
San Diego, CA). Categorical and quantitative variables were
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described as frequencies, percentage, and mean ± standard
deviation (SD). Data on demographic and clinical features
were compared between patients by the non-parametric Mann-
Whitney U-test or χ2 test, as appropriate. Spearman’s rank
correlation test was used for correlation in all analyses. For the
miRNA expression profile, data analysis was performed using
the supplied software (http://www.qiagen.com/it/shop/genes-
and-pathways/data-analysis-center-overview-page/), based on
Student’s t-test of the replicate 2∧(−1Ct) values for each
miRNA in the tested group and in the control group. P < 0.05
were considered statistically significant. Fold-change values >1
imply an upregulation while fold-change <1 imply down-
regulation. using miScript miRNA PCR array, a t-test was
used to identify significant differences in miRNA expression
profiles between UPIA patients who differentiated and those
who remained as UPIA during the follow-up. miRNA species
with a p < 0.05 was considered to be significant. We
performed a logistic regression model to determine the influence
of the dependent variable “differentiation to defined clinical
arthritis” by the independent variables that reached the value
of p < 0.25 at the univariate analysis. The values are expressed
as Odds Ratio (OR) and 95% Confidential Interval (95% CIs),
respectively. The Hosmer-Lemeshow test was used to assess the




Characteristics of Enrolled UPIA Patients
Fourty-two UPIA patients were enrolled in the study.
Demographical and clinical characteristics of the enrolled
UPIA cohort are summarized in Table 1. All UPIA patients
were negative for IgA-RF, IgM-RF and ACPA with a mono-
oligoarticular pattern of joint involvement. Moreover, none
of the patients had evidence of Reactive Arthritis. Among
the whole UPIA cohort, 6 (14.3%) patients reached a definite
diagnosis during the follow-up (within 6.5 ± 5.4 months) with
no differences among the three diagnosis (6.5 ± 7.7 months
for RA, 6.5 ± 7.8 months for SpA, and 6.5 ± 4.9 months for
PsA respectively). In particular, 2(33.3%) UPIA patients were
defined as having RA because of the development of >10 joints
involvement and both abnormal CRP and ESR (13), 2(33.3%)
as having PsA (due to the subsequent development of psoriasis,
psoriatic nail dystrophy and dactylitis) (14) and 2(33.3%) as
having SpA (due to the subsequent development of sacroiliitis
TABLE 1 | Demographic, clinical, and inflammatory characteristics of enrolled UPIA patients.
Whole UPIA Cohort (N = 42) Differentiation p
No (N = 36) Yes (N = 6)
Gender, female n(%) 28 (66.7) 24 (66.7) 4 (66.7) 1.00
Age, years (mean ± SD) 53.45 ± 13.89 55.17 ± 12.70 43.17 ± 17.46 0.10
Sympthoms duration, months (mean ± SD) 18.69 ± 16.37 16.69 ± 15.67 19.67 ± 21.43 0.56
ESR, mm/1st hour (mean ± SD) 22.07 ± 19.58 21.06 ± 19.19 28.00 ± 22.63 0.46
CRP, mg/L (mean ± SD) 6.39 ± 11.11 5.27 ± 7.96 12.72 ± 22.10 0.59
Swollen Joint count, (mean ± SD) 2.60 ± 1.86 2.53 ± 1.20 3.11 ± 1.93 0.40
AB positivity, n(%) 0 (0%) – – –
Genital swab positivity, n(%) 0 (0%) – – –
Throat swab positivity, n(%) 0 (0%) – – –
NSAIDs usage, n(%) 27 (64.8) 21 (58.3) 6 (100.0) 0.06
GC usage, n(%) 9 (21.4) 6 (16.7) 3 (50.0) 0.10
Smoking habit, n(%) 14 (33.3) 11 (30.5) 3 (50.0) 0.35
Diagnosis after differentiation
UPIA ⇒ RA – – 2 (33.3) –
UPIA ⇒ PsA – – 2 (33.3) –
UPIA ⇒ SpA – – 2 (33.3) –
IL-6 (PB), pg/ml (mean ± SD) 4.34 ± 5.04 3.49 ± 4.90 9.27 ± 2.36 0.01
IL-6 (SF), pg/ml (mean ± SD) 343.57 ± 167.16 320.67 ± 191.67 389.36 ± 105.81 0.98
VEGF-A (PB), pg/ml (mean ± SD) 42.21 ± 45.91 40.91 ± 45.77 48.49 ± 50.43 0.91
VEGF-D (PB), pg/ml (mean ± SD) 1016.91 ± 502.47 1001.11 ± 454.69 1095.87 ± 747.81 0.88
VEGF-A (SF)*, pg/ml (mean ± SD) 1388.68 ± 895.80 1236.92 ± 829.67 1694.21 ± 1130.89 0.38
VEGF-D (SF)*, pg/ml (mean ± SD) 338.62 ± 200.40 306.01 ± 186.50 403.82 ± 253.22 0.55
UPIA, Undifferentiated Peripheral Inflammatory Arthritis; ESR, Erytrocyte Sedimentation Rate; CRP, C-Reactive Protein; NSAIDs, Non Steroideal Anti-Inflammatory Drugs; GC,
corticosteroids; BMI, Body Mass Index; RA, Rheumatoid Arthritis; PsA, Psoriatic Arthritis; SpA, Spondyloarthritis; IL, interleukin; VEGF, Vascular Endothelial Growth Factor; PB, Peripheral
Blood; SF, Synovial Fluid; SD, Standard Deviation; *SF was available from 16 UPIA patients (5 UPIA patients who differentiated and 11 UPIA patients who remained as UPIA during
the follow-up); bold, p < 0.05 comparing UPIA patients who reached a defined clinical diagnosis during the follow-up (differentiation) vs. patients who remained as UPIA after 1 year
follow-up (no differentiation).
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on imaging) (15), respectively. Moreover, both UPIA patients
who differentiated into RA were confirmed as IgA/IgM-RF and
ACPA negative at the time of clinical differentiation without
developing bone erosions at X-Ray evaluation. UPIA patients
reaching a definite diagnosis during the follow-up did not
differ from UPIA patients who remained as UPIA afterwards in
terms of demographic and clinical [Erythrocyte Sedimentation
Rate (ESR), C-Reactive Protein (CRP) and symptoms duration
respectively] parameters as well as baseline pharmacological
treatment (NSAIDs and corticosteroids usage; Table 1).
UPIA patients who differentiated into definite arthritis, had
significantly higher baseline IL-6 PB levels (9.27 ± 2.36 pg/ml)
compared to patients who remained as UPIA (3.49± 4.90 pg/ml;
p = 0.01), whereas comparable PB VEGF-A and VEGF-D levels
were found comparing the two subgroups (Table 1). At baseline,
there was direct correlation between IL-6 and CRP PB levels in
the whole UPIA cohort (R= 0.42; p= 0.03). Finally, considering
UPIA patients whose SF was available at study entry (n = 16)
no differences in baseline VEGF-A and VEGF-D SF levels
were found, stratifying UPIA patients based on the subsequent
differentiation (Table 1 and Supplementary Table 2).
Baseline Histological Features of Synovial
Tissue of UPIA Patients Are Related to the
Achievement of a Defined Diagnosis
Afterwards
At baseline, each enrolled UPIA patient underwent ST biopsy
of the knee which was tested through immunohistochemistry
for the presence of CD68+, CD21+, CD3+, CD20+ cells, and
CD31+ vessels count showing that CD68+ cells represent the
most common inflammatory cells (p < 0.001) in the lining of
the synovial tissue of seronegative UPIA patients (Figure 1A)
whereas a comparable distribution was found in the sublining
area concerning the analyzed inflammatory cells (p = 0.06;
Figure 1B). Among the assessed inflammatory cells, the IHC
scores for CD68+ and CD3+ cells, in ST of seronegative UPIA
patients, directly correlates with the entity of tissue vasculature,
expressed by the mean number of CD31+ vessels (R = 0.42;
p = 0.005 and R = 0.37; p = 0.015 for lining and sublining
IHC scores for CD68+ cells; R = 0.29 p = 0.05 and R = 0.43;
p = 0.004 for lining and sublining IHC scores for CD3+ cells;
Figures 1C,D) whereas no significant correlation was found
between lining and sublining IHC scores for CD20+ cells and
the mean number of CD31+ vessels (R =0.25, p = 0.12, and
R = 0.21, p = 0.18 for lining and sublining CD20+ cells
respectively). Considering the synovial tissue pattern in the whole
cohort, a follicular synovitis was found in 6(14.3%) seronegative
UPIA patients without significant difference stratifying UPIA
patients according to the subsequent differentiation [2(33.3%)
of UPIA patients who differentiated into definite arthritis had
baseline follicular synovitis vs 4(11.1%) UPIA patients who
remained as UPIA had baseline follicular synovitis (p = 0.14)]
(Figure 1E). However, analyzing the distribution of synovial
tissue resident inflammatory cells at baseline (Figures 2A–P),
significantly higher histological scores for lining CD68+ cells
(2.22 ± 0.65 vs. 1.45 ± 0.41, p = 0.005; Figure 3A), sublining
FIGURE 1 | (A–E) Synovial tissue immunohistochemical scores for CD68+, CD21+, CD20+, CD3+ cells of enrolled seronegative UPIA patients and synovitis
pathotype distribution. (A,B) Baseline lining and sublining IHC scores for CD68+, CD20+ and CD3+ cells of synovial tissue of UPIA patients cohort (**p < 0.001
ANOVA Test); Mann-Whitney test for all comparisons: lining CD68+ vs lining CD20+ cells (1.57 ± 0.52 vs. 0.12 ± 0.40; p < 0.001) and lining CD68+ cells vs lining
CD3+ cells (1.57 ± 0.52 vs. 0.25 ± 0.42; p < 0.001); CD20+ cells vs lining CD3+ cells (0.12 ± 0.40 vs. 0.25 ± 0.42; p = 0.13) (Data on graphs represent mean ±
SD); (C) Correlation between lining and sublining ST IHC scores of CD68+ cells and CD31+ vessels count in the whole cohort of seronegative UPIA patients; (D)
Correlation between lining and sublining ST IHC scores of CD3+ cells and CD31+ vessels count in the whole cohort of seronegative UPIA patients; (E) Example
photos of H&E staining of ST of UPIA patients with follicular (f) or diffuse (d) synovitis pattern (magnification 20x). UPIA, Undifferentiated Peripheral Inflammatory
Arthritis; CD, Cluster designation; IHC, Immunohistochemistry; ST, Synovial Tissue; L, Lining; SL, Sublining; H&E, Haematoxylin and Eosin; SD, Standard Deviation.
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FIGURE 2 | (A–P) Ultrasound assessment and immunohistochemistry for CD68+, CD21+, CD20+, CD3+ cells and CD31+ vessels of synovial tissue of enrolled
UPIA patients based on the clinical differentiation. (A) Example photo of the ultrasound assessment of knee joint of UPIA patient who remained as UPIA afterwards;
(B) Example photo of the ultrasound assessment of knee joint of UPIA patient who differentiated into RA afterwards; (C) Example photo of the ultrasound assessment
of knee joint of UPIA patient who differentiated into PsA afterwards; (D) Example photo of the ultrasound assessment of knee joint of UPIA patient who differentiated
into SpA afterwards; Example photos of CD68 (Red)/CD21 (Brown) staining of ST biopsies from UPIA patients who (E) remained as UPIA, (F) differentiated into RA,
(G) differentiated into PsA or (H) differentiated into SpA afterwards (Magnification 20X); Example photos of CD3 (Red)/CD20 (Brown) staining of ST biopsies from UPIA
patient who (I) remained as UPIA, (J) differentiated into RA, (K) differentiated into PsA or (L) differentiated into SpA afterwards (Magnification 20X); Example photos of
CD31 (Brown) staining of ST biopsies from UPIA patient who (M) remained as UPIA, (N) differentiated into RA, (O) differentiated into PsA or (P) differentiated into SpA
afterwards (Magnification 20X); US picture with PD scale of the knee used for ST biopsy is shown next to the corresponding patient; ST, synovial tissue; UPIA,
Undifferentiated Peripheral Inflammatory Arthritis; CD, Cluster designation; RA, Rheumatoid Arthritis; SpA, Spondyloarthritis; PsA, Psoriatic Arthritis.
CD68+ cells (1.44 ± 0.45 vs. 1.00 ± 0.44, p = 0.04), sublining
CD3+ cells (1.88 ± 0.89 vs. 0.81 ± 0.65, p = 0.002; Figure 3B)
and higher CD31+ vessels count (28.17 ± 2.76 vs. 14.88 ±
7.39, p < 0.001; Figure 3C) were found in UPIA patients who
differentiated into defined seronegative arthritis than patients
who remained as UPIA during the follow-up. Interestingly, both
UPIA patients who differentiated into RA had follicular synovitis
at baseline compared to none of UPIA patients who differentiated
into PsA or SpA.
Baseline GSUS and PDUS Scores Are
Associated With Clinical Differentiation
and Directly Correlate With Histological
Scores of Synovial Resident Inflammatory
Cells in UPIA Patients
The US assessment showed that enrolled seronegative UPIA
patients showed GSUS of and PDUS scores of 1.36 ± 0.77 and
1.45 ± 0.88 respectively. Moreover, at baseline, UPIA patients
who reached a definite diagnosis during the follow-up, had
significantly higher GSUS (2.00 ± 0.63) and PDUS scores (1.50
± 0.84) compared to patients who remained as UPIA afterwards
(1.25 ± 0.44 for GSUS score, p = 0.01; and 0.58 ± 0.60 for
PDUS score respectively, p = 0.02; Figure 3D). Moreover, at
baseline, GSUS and PDUS scores directly correlated with ST
histological features in terms of synovial resident inflammatory
cells. In particular, baseline GSUS score directly correlated with
CD68+ lining (R = 0.55; p < 0.001) and sublining (R = 0.37;
p = 0.02) scores, CD3+ sublining score (R = 0.47; p = 0.002)
and CD31+ vessels count (R= 0.41; p= 0.01). Similarly, baseline
PDUS score directly correlated with CD68+ lining (R = 0.36;
p = 0.02) and sublining (R = 0.33; p = 0.03) scores, CD3+
sublining score (R = 0.47; p = 0.002) and CD31+ vessels count
(R= 0.52; p < 0.001; Supplementary Figure 1).
Whole Synovial Tissue miRNA Expression
Profile Is Altered in Seronegative UPIA
Patients Based on the Clinical
Differentiation and Is Related to TNF
Expression and Histological Features of
Synovial Tissue
To assess if seronegative UPIA patients differ in terms of the
whole synovial tissue epigenetic signature, based on the clinical
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FIGURE 3 | (A–D) Immunohistochemistry scores of synovial tissue of UPIA patients based on the differentiation during the follow-up. (A) Lining IHC scores for
CD68+, CD21+, CD3+, and CD20+ cells in ST of UPIA patients based on the differentiation during the follow-up; *p = 0.005 lining CD68+ cells IHC score
comparing UPIA patients who differentiated compared to patients who remained as UPIA during the follow-up; (B) Sublining IHC scores for CD68+, CD21+, CD3+,
and CD20+ cells in ST of UPIA patients based on the differentiation during the follow-up; *p = 0.04 sublining CD68+ cells IHC score comparing UPIA patients who
differentiated vs. patients who remained as UPIA during the follow-up; **p = 0.002 sublining CD3+ cells IHC score comparing UPIA patients who differentiated vs.
patients who remained as UPIA during the follow-up; (C) IHC scores for CD31+ vessels in ST of UPIA patients based on the differentiation during the follow-up;
*p < 0.001 CD31+ vessels count comparing UPIA patients who differentiated vs patients who remained as UPIA during the follow-up; (D) Baseline GSUS and PDUS
scores in seronegative UPIA patients who reached a definite diagnosis during the follow-up compared to UPIA patients who remained as UPIA (*p < 0.001 for GSUS
and *p = 0.01 for PDUS respectively); (All data on graphs represent mean ± SD); IHC, Immunohistochemistry; CD, Cluster Designation; UPIA, Undifferentiated
Peripheral Inflammatory Arthritis; SD, Standard Deviation.
differentiation likelihood, we analyzed, in the synovial tissue,
the expression of a panel of miRNAs selected on the basis of
their relevance in the regulation of inflammatory cells activation
(Supplementary Figure 2). Overall, our analysis showed that the
expression of miR-346 and miR-214 was significantly decreased
in UPIA patients who reached a definite diagnosis during the
follow-up compared to UPIA patients who remained as UPIA
(0.44 fold change; p = 0.017 and 0.44 fold change; p = 0.023
for miR-346 and miR-214 respectively; Table 2). As shown in
Figure 4A, Volcano scatter plot showed that miR-346 and miR-
214 were the most down-regulated miRNAs (upper left corner of
the plot) in UPIA patients who differentiated during the follow-
up than UPIA patients who remained as UPIA. In particular, as
shown in Figure 4B, UPIA patients who differentiated during
the follow-up showed, at baseline, significantly lower expression
of miR-346 and miR-214 at synovial tissue level compared
to UPIA patients who remained as UPIA (p = 0.017 and
p = 0.023 for miR-346 and miR-214 respectively). Moreover,
at baseline miR-346 expression in the whole synovial tissue
inversely correlated with the lining CD68+ cells IHC score
(R = −0.64; p = 0.04; Figure 4C) and with the synovial tissue
CD31+ vessels count (R = −0.66; p = 0.03) in seronegative
UPIA patients (Figure 4D). Finally, as shown in Figure 4E, UPIA
patients who differentiated during the follow-up showed higher
baseline expression of TNF in the synovial tissue than patients
who remained as UPIA (p = 0.01), directly correlating with the
baseline synovial tissue CD31+ vessels count (R= 0.72; p= 0.02;
Figure 4F).
Baseline GSUS and PDUS Scores and
CD31+ Vessels Count Are Independent
Factors Associated With Clinical
Differentiation in UPIA Patients
To define the best cut-off value for CD68+ cells lining and
sublining scores, CD3+ cells sublining score, CD31+ vessels
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FIGURE 4 | (A–F) microRNA panel of the whole synovial tissue of UPIA patients based on the clinical differentiation during the follow-up and its correlations with TNF
tissue expression and histological features. (A) Volcano plot showing expression of miRNAs in the whole synovial tissue of UPIA patients; Color scheme: green
decreased expression; Red, Increased expression; Black, Unchanged. The miRNAs that are significantly altered between the two groups are located above the
horizontal black line corresponding to p < 0.05; (B) miR-346 and miR-214 expression in whole synovial tissue of seronegative UPIA stratified based on the clinical
differentiation during the follow-up (*p = 0.02; **p = 0.02) (Data on graphs represent mean ± SD); (C) Correlation between miR-346 expression in the whole synovial
tissue of UPIA patients and lining CD68+ cells IHC semi-quantitative score; Red, UPIA patients who differentiated during the follow-up; Gray, UPIA patients who
remained as UPIA during the follow-up; (D) Correlation between miR-346 expression in the whole synovial tissue of UPIA patients and CD31+ vessels count (mean);
Red, UPIA patients who differentiated during the follow-up; Gray, UPIA patients who remained as UPIA during the follow-up; (E) TNF expression in whole synovial
tissue of seronegative UPIA stratified based on the clinical differentiation during the follow-up (*p = 0.01) (Data on graphs represent mean ± SD); (F) Correlation
between TNF expression in the whole synovial tissue of UPIA patients and CD31+ vessels count (mean); Red, UPIA patients who differentiated during the follow-up;
Gray, UPIA patients who remained as UPIA during the follow-up; SD, Standard Deviation; CD, Cluster Designation; UPIA, Undifferentiated Peripheral Inflammatory
Arthritis.
count and IL-6 PB levels, able to identify UPIA patients
who reached a defined diagnosis during the follow-up, ROC
analysis was performed for each parameter (Supplementary
Table 3). UPIA patients who reached a definite diagnosis
during the follow-up had more likely baseline GSUS score ≥1.5
(83.3%) and PDUS score ≥1.5 (66.7%) than UPIA patients
who remained as UPIA (25.0% patients with GSUS ≥1.5,
p = 0.01 and 5.6% patients with PDUS ≥1.5, p = 0.002;
Figure 5A). As shown in Figure 5B, UPIA patients who reached
a definite diagnosis during the follow-up had more baseline
lining CD68+ cells score ≥2.16 (50.0%), sublining CD68+
cells score ≥1.16 (83.3%), sublining CD3+ cells score ≥1.16
(83.3%), and CD31+ vessels count ≥24.3 (83.3%) compared
to patients who remained as UPIA (5.6% patients with lining
CD68+ cells score ≥2.16, p = 0.01; 30.6% patients with
sublining CD68+ cells score ≥1.16, p = 0.02; 16.7% patients
with sublining CD3+ cells score ≥1.16, p = 0.003 and 8.3%
patients with CD31+ vessels score ≥24.3, p < 0.001). Moreover,
UPIA patients who differentiated within 1 year, had more
likely IL-6 PB levels ≥4.75 pg/ml (100.0%) than UPIA patients
who remained as UPIA (21.7%; p = 0.01). Finally, the logistic
regression analysis (data not shown) demonstrated that having
baseline GSUS and PDUS scores ≥1.5 at US assessment [OR:
22.93 (95%CI:0.98–534.31)] and CD31+ vessels count ≥24.3
[OR: 23.66 (95%CI: 1.50–373.00)] are two independent factors
associated with future achievement of defined arthritis in
seronegative UPIA patients (Hosmer-Lemeshowtest: p= 0.35).
DISCUSSION
In daily practice, a large amount of patients who present
with recent-onset arthritis have UPIA at the first clinical
examination, however there is still an unmet medical need in the
identification of possible diagnostic and prognostic biomarkers
to be applied in such patients. In the current study, we found
that ST of seronegative UPIA patients show specific microRNA
profiling based on the likelihood chance of clinical future
differentiation. Moreover, we demonstrated that the combined
analysis of histological and US features of ST, at the first clinical
examination, may help in the identification of UPIA patients with
higher chance of further differentiation.
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TABLE 2 | Baseline fold change expression of microRNAs in whole synovial tissue
comparing seronegative UPIA patients who achieved diagnosis of definite
seronegative arthritis vs. UPIA patients who remained as UPIA during the
follow-up.
Diff UPIA vs. no-Diff UPIA

















































TABLE 2 | Continued
Diff UPIA vs. no-Diff UPIA






































miRNA profiling was analysed in the whole synovial tissue total RNA samples obtained
from seronegative UPIA patients z(6 UPIA patients who reached a definite diagnosis of
seronegative arthritis during the follow-up and 4 UPIA patients who remained as UPIA);
Columns highlighted in bold represent miRNAs that show significant differential expression
between the two groups (p < 0.05); Red-highlighted values indicate up-regulated miRNA
species whereas green-highlighted values indicate down-regulated miRNA species in ST;
MiRNA, microRNA.
As known, ST biopsy is not routinely performed in
clinical practice (20), since often, history-taking, physical and
radiographic examination, as well as serum and autoimmune
markers are sufficient to make a defined diagnosis (1). However,
autoantibody negativity may increase the difficulty in reaching
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FIGURE 5 | (A,B) Baseline GSUS, PDUS and immunohistochemistry cut-off values for differentiation into seronegative definite arthritis in UPIA patients. (A)
Distribution of GSUS and PDUS cut-off values in UPIA patients based on the differentiation during the follow-up; 5(83.3%) UPIA patients who reached a defined
diagnosis during the follow-up had baseline GSUS score ≥1.5 vs. 9(25.0%) patients who remained as UPIA during the follow-up had baseline GSUS score ≥1.5,
*p = 0.01; 4(66.7%) UPIA patients who reached a defined diagnosis during the follow-up had baseline PDUS score ≥1.5 vs. 2(5.6%) patients who remained as UPIA
during the follow-up had baseline PDUS score ≥1.5, *p = 0.002; (B) Distribution of IHC cut-off values in UPIA patients based on the differentiation during the
follow-up; 3(50.0%) UPIA patients who reached a defined diagnosis during the follow-up had baseline lining CD68+ cells score ≥2.16 vs. 2(5.6%) patients who
remained as UPIA during the follow-up had baseline lining CD68+ cells score ≥2.16, *p = 0.01; 5(83.3%) UPIA patients who reached a defined diagnosis during the
follow-up had baseline sublining CD68+ cells score ≥1.16 vs. 11(30.6%) patients who remained as UPIA during the follow-up had baseline lining CD68+ cells score
≥1.16, **p = 0.02; 5(83.3%) UPIA patients who reached a defined diagnosis during the follow-up had baseline sublining CD3+ cells score ≥1.16 vs. 6(16.7%)
patients who remained as UPIA during the follow-up had baseline sublining CD3+ cells score ≥1.16, ***p = 0.003; 5(83.3%) UPIA patients who reached a defined
diagnosis during the follow-up had baseline CD31+ vessels count ≥24.3 vs. 3(8.3%) patients who remained as UPIA during the follow-up had baseline CD31+
vessels count ≥24.3, ****p < 0.001. Data are shown as percentage of UPIA patients fulfilling the different cut-off values of US parameters or IHC scores, based on
their clinical differentiation during the follow-up (all data on graphs represent mean ± SD). GSUS, Gray Scale Ultrasonography; PDUS, Power Doppler
Ultrasonography; IHC, Immunohistochemistry; CD, Cluster Designation; UPIA, Undifferentiated Peripheral Inflammatory Arthritis; SD, Standard Deviation.
a definite classification. Therefore, in our study we included
only IgA/IgM-RF and ACPA negative UPIA patients to assess
the possible prognostic role of ST biopsy in foreseeing the future
clinical development into defined arthritis. Kraan et al. previously
demonstrated that immunohistochemical analysis of synovial
tissue from patients with early undifferentiated arthritis may help
in the differentiation of non-RA from RA patients with increased
plasmacells, B cells and macrophages infiltration in the latter
group (7). In our study, we found that CD68+ cells represent
the most abundant inflammatory cells within the ST with a direct
correlation with US parameters in seronegative UPIA. Moreover,
we found that seronegative UPIA patients who differentiate
into further defined arthritis, show higher expression of lining
and sublining CD68+ cells, sublining CD3+ cells, increased
number of CD31+ vessels and higher IL-6 PB levels than
patients who remain as UPIA during the follow-up. Among
different immunohistochemical parameters, logistic regression
analysis showed that having a CD31+ vessels count ≥24.3 is
an independent factor associated with further differentiation in
seronegative UPIA patients. To avoid therapeutic bias, in the
present study we enrolled only UPIA patients taking NSAIDs or
corticosteroids compared to the study by Kraan and colleagues
(7), in which DMARDs including antimalarials, sulphasalazine
and gold were allowed.
The use of US in UPIA patients assessment is not routinely
recommended by experts for diagnostic and prognostic purposes
(1), despite US may offer advantages, being more sensitive than
physical examination and X-rays. To date, few studies revealed
that PDUS and GSUS parameters may be considered potential
candidates in UPIA patients examination (6). Recently, Horton
SC, et al investigated the power of US assessment in UPIA
patients at risk of RA development, showing that (9/42) UPIA
patients progressed toward definite diagnosis of RA during
1 year follow-up and that GSUS synovitis was a predictive
factor of disease progression (5). In our study we assessed,
for the first time, the prognostic role of US in combination
with ST biopsy in foreseeing the future differentiation into
defined arthritis in seronegative UPIA patients showing that,
at baseline, PDUS and GSUS scores are directly associated
with histological synovial inflammation in terms of CD68+,
CD3+ cells and CD31+ vessels. Moreover, logistic regression
analysis revealed that in seronegative UPIA patients, having at
baseline PDUS and GSUS scores ≥1.5, is an independent factor
associated with clinical differentiation afterwards, increasing
the evidence supporting the utility of US assessment in the
management of seronegative UPIA patients. These results
strengthen the link between US detected synovitis and histology
supporting its feasible use in the clinical management of UPIA
patients.
The analysis of vascular morphology seemed to increase the
classification power to distinguish between RA (with straight
pattern) from PsA or SpA patients (with tortuous pattern) at
arthroscopic evaluation (21). Therefore, since the angiogenic
processes play crucial role in the initiation and perpetuation of
synovial inflammation, allowing the influx of inflammatory cells
in ST (22, 23), VEGF-A and VEGF-D plasma and synovial fluid
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levels were tested. We found that baseline VEGF-A and VEGF-
D plasma and synovial fluid levels are not different in UPIA
patients who reach a definite diagnosis compared to patients
who remain as UPIA confirming previous data in a smaller
study population (24). The number of patients who evolved
into RA, PsA or SpA was insufficient to determine possible
differences among the three diseases. Yet the mean number
of CD31+ vessels in ST, along with US parameters appear to
be the most efficient way to identify UPIA patients with high
likelihood to differentiate into a definite chronic seronegative
arthritis.
To date, few data have been produced on the role of miRNA
as predictive tools in arthritis development and prognosis,
with scarce studies only assessing miRNAs profile in peripheral
blood derived cells of seropositive individuals at risk of arthritis
development (13) with no data on ST. In our knowledge, this is
the first study analyzing the expression of a panel of different
miRNA species in the whole synovial tissue of ACPA/IgA-
IgM negative UPIA patients stratified based on their clinical
differentiation toward definite seronegative arthritis within 1
year follow-up. Among the assessed miRNAs, miR-346, and
miR-214 arose to be significantly repressed, at baseline, in ST
of seronegative UPIA patients who differentiated compared to
patients who remained as UPIA during the follow-up. To date,
very limited data were produced on the effect of miR-214
downregulation on the pathogenesis of arthritis. Lai NS et al
recently found that TNF-α stimulation is able to significantly
reduce miR-214 expression from T cells in vitro and that the
transfection with miR-214 mimic conversely suppresses TNF-
α signal, providing a survival signal for T cells through the
ERK/JNK pathway (25–27). MiR-346 has been demonstrated to
play a role in the control of the inflammatory response acting
as a positive regulator of Tristetraprolin, a RNA binding protein
that destabilizes TNF mRNA, acting as a negative regulator of
TNF synthesis (28). Moreover, miR-346 was found to be involved
in the regulation of Bruton Tyrosine Kinase involved in the
TNF release in RA (29, 30). In our cohort of seronegative UPIA
patients, the expression ofmiR-346 in ST inversely correlates with
synovial IHC scores of CD68+ cells and CD31+ vessels count,
suggesting a possible link between miR-346 downregulation
and ST inflammation in terms of immune cells infiltrate and
vascularity. Moreover, we found that seronegative UPIA patients
who achieved a definite diagnosis during the follow-up showed,
at baseline, higher expression of TNF at ST level, supporting
the notion that seronegative UPIA patients with higher risk of
clinical differentiation may have more stable TNF mRNA due to
miR-346 downregulation (28). This hypothesis is supported by
the finding that the TNF expression in the ST directly correlates,
at baseline, with the entity of the tissue vasculature (expressed by
the CD31+ vessels count) which enables inflammatory cells ST
influx.
In conclusion, we believe that this study results may
have an impact for the daily management of seronegative
UPIA patients as supported by the direct association between
synovial membrane US features and histologically proven
tissue inflammation associated with their chance of future
differentiation. Moreover, despite mono or oligoarticular joint
involvement, seronegative UPIA patients with high likelihood of
clinical differentiation are characterized by aberrant microRNA
signature at ST level with a direct correlation with histological
and US features of ST supporting the need for a more aggressive
treatment.
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